pSivida obtained fantastic results from the six-month safety
records of its first phase 3 pivotal clinical trial for Medidur for posterior
uveitis.
there has been a small average boom in intraocular stress
(IOP) in Medidur-handled eyes thru six months relative to control.
The company plans to fulfill with the FDA next sector and
affirm that records from two trials will continue to be required for a U.S.
new drug utility currently planned for the first 1/2 of calendar 2017.
No comments:
Post a Comment